Archivserver der Deutschen Nationalbibliothek

58. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T,
Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE. Randomized, double-blind,
multicenter study of the Endeavor zotarolimus-eluting
phosphorylcholine-encapsulated stent for treatment of native coronary
artery lesions. Clinical and angiographic results of the ENDEAVOR II
Trial. Minerva Cardioangiol. 2007; 55:1-18.
59. Stone GW ES, Cannon L, Mann JT, Greenberg JD, Spriggs D,
O´Shaughnessy CD, De Maio S. Comparison of a polymer-based
paclitaxel-eluting stent with a bare metal stent in patients with complex
coronary artery disease: a randomized controlled trial. Minerva
Cardioangiol. 2007; 55(1):1-18.
60. Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C, Gerckens U,
Lansky AJ, Fitzgerald PJ. Six- and twelve-month results from first
human experience using everolimus-eluting stents with bioabsorbable
polymer. Circulation. 2004; 109:2168-71.
61. Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Tielbeek A,
Anderson J, Wiesinger B, Tepe G, Lansky A, Mudde C, Tielemans H,
Beregi JP. Sirolimus-eluting versus bare nitinol stent for obstructive
superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv
Radiol. 2005; 16:331-8.
62. Zeller T, Rastan A, Rothenpieler U, Muller C. Restenosis after stenting
of atherosclerotic renal artery stenosis: is there a rationale for the use of
drug-eluting stents? Catheter Cardiovasc Interv. 2006; 68:125-30.
63. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new
antifungal antibiotic. II. Fermentation, isolation and characterization. J
Antibiot (Tokyo). 1975; 28:727-32.
64. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new
antifungal antibiotic. I. Taxonomy of the producing streptomycete and
isolation of the active principle. J Antibiot (Tokyo). 1975; 28:721-6.
67